Join NOF AMERICA CORPORATION for an upcoming Xtalks panel discussion
Join NOF AMERICA CORPORATION for an upcoming Xtalks panel discussion, "Streamline Targeted LNP Development to Improve Preclinical Translation."
A Strategic Collaboration to Accelerate LNP-based Drug Development
NOF Corporation joins the LNP Alliance, bringing advanced lipid expertise to accelerate lipid nanoparticle drug development.
Polysorbate 80 (HX2)™ Is in Compliance With The Chinese Pharmacopoeia
Polysorbate 80 (HX2)™, NOF AMERICA’s ultrapure polysorbate 80, has achieved compliance with USP, EP, JP, and the Chinese Pharmacopoeia (ChP for injection), enabling pharmaceutical product development for the Chinese market.